Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32943
Title: Effect of CannEpil® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial.
Austin Authors: Manning, Brooke;Hayley, Amie C ;Catchlove, Sarah;Shiferaw, Brook;Stough, Con;Downey, Luke A
Affiliation: Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia.
Institute for Breathing and Sleep
International Council for Alcohol, Drugs, and Traffic Safety
Seeing Machines, Melbourne, VIC, Australia.
Issue Date: May-2023
Date: 2023
Publication information: Journal of Psychopharmacology (Oxford, England) 2023; 37(5)
Abstract: Medicinal cannabis products containing Δ9-tetrahydrocannabinol (THC) are increasingly accessible. Yet, policy guidelines regarding fitness to drive are lacking, and cannabinoid-specific indexations of impairment are underdeveloped. To determine the impact of a standardised 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg THC on simulated driving performance, relative to placebo and whether variations in vehicle control can be indexed by ocular activity. A double-blind, within-subjects, randomised, placebo-controlled, crossover trial assessed 31 healthy fully licensed drivers (15 male, 16 female) aged between 21 and 58 years (M = 38.0, SD = 10.78). Standard deviation of lateral position (SDLP), standard deviation of speed (SDS) and steering variability were assessed over time and as a function of treatment during a 40 min simulated drive, with oculomotor parameters assessed simultaneously. Oral fluid and plasma were collected at 30 min and 2.5 h. CannEpil did not significantly alter SDLP across the full drive, although increased SDLP was observed between 20 and 30 min (p < 0.05). CannEpil increased SDS across the full drive (p < 0.05), with variance greatest at 20-30 min (p < 0.001). CannEpil increased fixation duration (p < 0.05), blink rate (trend p = 0.051) and decreased blink duration (p < 0.001) during driving. No significant correlations were observed between biological matrices and performance outcomes. CannEpil impairs select aspects of vehicle control (speed and weaving) over time. Alterations to ocular behaviour suggest that eye tracking may assist in determining cannabis-related driver impairment or intoxication. Australian and New Zealand Clinician Trials Registry, https://anzctr.org.au(ACTRN12619000932167).
URI: https://ahro.austin.org.au/austinjspui/handle/1/32943
DOI: 10.1177/02698811231170360
ORCID: 0000-0001-5233-8191
0000-0002-4470-4718
Journal: Journal of Psychopharmacology (Oxford, England)
Start page: 472
End page: 483
PubMed URL: 37129083
ISSN: 1461-7285
Type: Journal Article
Subjects: cannabidiol
driving performance
oculomotor
Δ9-tetrahydrocannabinol
Cannabidiol/pharmacology
Appears in Collections:Journal articles

Show full item record

Page view(s)

60
checked on Oct 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.